FRANCE PSORIATIC ARTHRITIS TREATMENT RATE AND USAGE OF BIOLOGICTHERAPIES, BY DISEASE SEVERITY AND LINE OF THERAPY

GERMANY PSORIATIC ARTHRITIS TREATMENT RATE AND USAGE OF BIOLOGICTHERAPIES, BY DISEASE SEVERITY AND LINE OF THERAPY

Humira and Enbrel will remain the dominant therapies in psoriatic arthritis (PsA), despite significant pressure from the launch of biosimilars. This report addresses the following questions: - To what extent will the launch of cheaper biosimilars affect sales of the longstanding tumor necrosis factor (TNF)-alpha inhibitors? -...

Cancer is the leading and second largest cause of death across the globe. The disease is characterized by disordered and deregulated cellular and stromal explosion along with reduced cell death and growth factor deprivation, and such other factors. There are many biological therapies that have been approved and being used by various cancer...

Whether they would be willing to sacrifice any benefit in exacerbation reduction for improved secondary considerations (such as FEV-## asthma control scores and ACQ-## asthma control scores) in a typical severe asthma patient being treated with a biologictherapy?

PROVIDES A SWOT ANALYSIS OF OTHER BIOLOGICTHERAPIES (CAMPATH/LEMTRADA AND RITUXAN).

EFFICACY OF OTHER BIOLOGICTHERAPIES (CAMPATH/LEMTRADA AND RITUXAN) IN GVHD

Opportunity Analyzer: Graft-Versus-Host Disease - Opportunity Analysis and Forecasts to 2023 Summary The main drivers of growth in graft versus host disease over the 2013-2023 forecast period include the increasing numbers of allogeneic hematopoietic stem cell transplants and the increasing use of biologic off-label...

They were asked to rank seven therapy areas according to the number of marketed therapies these would experience compared to one another (with ## having the lowest number of marketed therapies and ## the highest).